Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics is expected to have a strong year ahead as it continues to execute on the ongoing Phase 2a GAlette study for OpRegen, which is evaluating subretinal delivery optimization and safety. The company has already achieved several milestones under its partnership with Roche and Genentech, including positive 36-month data for OpRegen in geographic atrophy secondary to Age-Related Macular Degeneration and a cash milestone payment. Additionally, Lineage is making progress in expanding its pipeline and manufacturing capabilities, with a focus on developing treatments for other degenerative diseases such as spinal cord injury and Type 1 diabetes.

Bears say

Lineage Cell Therapeutics is a clinical-stage biotech company that faces significant risks in its operations, including clinical/regulatory and financial risk, as well as potential legal and IP risks. Despite recent progress in its allogeneic cell transplant platform and potential partnerships, the company faces uncertain commercial success in its various programs, highlighted by a relatively modest 2023 revenue projection of just $24.9 million, which may pose challenges to its long-term sustainability and market share. Moreover, with a current market cap of $358.6 million, the company has a relatively high valuation for a clinical-stage biotech, potentially exposing investors to further downside risk if its pipeline development experiences setbacks or delays.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.